product monograph - Sivem Pharmaceuticals
... is confirmed, BICALUTAMIDE should be discontinued and the patient treated appropriately. Skin In rare cases, photosensitivity reactions have been reported for patients taking bicalutamide. Patients should be advised to avoid direct exposure to excessive sunlight or UV-light while on bicalutamide and ...
... is confirmed, BICALUTAMIDE should be discontinued and the patient treated appropriately. Skin In rare cases, photosensitivity reactions have been reported for patients taking bicalutamide. Patients should be advised to avoid direct exposure to excessive sunlight or UV-light while on bicalutamide and ...
Slide Set
... • Substantially fewer patients reported that nausea and vomiting interfered with daily living when EMEND was added to control regimens* vs. control regimens** alone (p<0.001) *EMEND with — Day 1: EMEND 125 mg PO, Zofran® 32 mg IV, and dexamethasone 12 mg PO ...
... • Substantially fewer patients reported that nausea and vomiting interfered with daily living when EMEND was added to control regimens* vs. control regimens** alone (p<0.001) *EMEND with — Day 1: EMEND 125 mg PO, Zofran® 32 mg IV, and dexamethasone 12 mg PO ...
Clinical Pharmacokinetics Of
... orally, but it may be administered I.M & I.V. It is frequently administered as the sodium salt, which is approximately 91%, when phenobarbital is administered parenterally; it’s usually administered at rate of no more than 50mg/min. to avoid toxicities associated with the propylene glycol diluent. ...
... orally, but it may be administered I.M & I.V. It is frequently administered as the sodium salt, which is approximately 91%, when phenobarbital is administered parenterally; it’s usually administered at rate of no more than 50mg/min. to avoid toxicities associated with the propylene glycol diluent. ...
Product Monograph Template - Standard
... some patients additional factor VIII was given. In more than half of the reported cases, treatment with PIs was continued or reintroduced. A causal relationship between PI therapy and these events has not been established; however, the frequency of bleeding episodes should be closely monitored in pa ...
... some patients additional factor VIII was given. In more than half of the reported cases, treatment with PIs was continued or reintroduced. A causal relationship between PI therapy and these events has not been established; however, the frequency of bleeding episodes should be closely monitored in pa ...
Intravenous Acetaminophen and Intravenous Ketorolac
... Like ketorolac, acetaminophen must be able to cross the BBB to exert CNS effects. One study has shown that acetaminophen readily crosses the BBB in children.17 In that study, CSF levels of acetaminophen were detectable within 5 minutes of IV administration. In approximately 1 hour, measured CSF and ...
... Like ketorolac, acetaminophen must be able to cross the BBB to exert CNS effects. One study has shown that acetaminophen readily crosses the BBB in children.17 In that study, CSF levels of acetaminophen were detectable within 5 minutes of IV administration. In approximately 1 hour, measured CSF and ...
highlights of prescribing information
... Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa) Ribavirin may cause birth defects and/or death of the exposed fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin therapy should not be started unless a report of a ...
... Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa) Ribavirin may cause birth defects and/or death of the exposed fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin therapy should not be started unless a report of a ...
Cost-effectiveness of anticoagulants for suspected
... to confirm or rule out HIT are ordered. While awaiting the results, patients are at risk of VTE or major bleeding. We used 3% as the mean incidence of confirmed HIT based on the reported incidence of 1% to 5% in inpatients in the United States.2,4 Although higher percentages of up to 10% have been rep ...
... to confirm or rule out HIT are ordered. While awaiting the results, patients are at risk of VTE or major bleeding. We used 3% as the mean incidence of confirmed HIT based on the reported incidence of 1% to 5% in inpatients in the United States.2,4 Although higher percentages of up to 10% have been rep ...
PRODUCT MONOGRAPH PrLUVOX
... On rare occasions development of a serotonin syndrome or neuroleptic malignant syndrome-like events have been reported in association with treatment of LUVOX®, particularly when given in combination with other serotonergic and / or neuroleptic/antipsychotic drugs. As these syndromes may result in po ...
... On rare occasions development of a serotonin syndrome or neuroleptic malignant syndrome-like events have been reported in association with treatment of LUVOX®, particularly when given in combination with other serotonergic and / or neuroleptic/antipsychotic drugs. As these syndromes may result in po ...
Keppra, INN-Levetiracetam
... Levetiracetam, also known as ucb L059, is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy. The daily dose is to be administered in two equally divided doses. As adjunctive therapy, the initial therapeutic r ...
... Levetiracetam, also known as ucb L059, is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy. The daily dose is to be administered in two equally divided doses. As adjunctive therapy, the initial therapeutic r ...
PRODUCT MONOGRAPH METADOL
... Laboratory studies, both in vivo and in vitro, have demonstrated that methadone inhibits cardiac potassium channels and prolongs the QT interval. Cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. These cases appear to b ...
... Laboratory studies, both in vivo and in vitro, have demonstrated that methadone inhibits cardiac potassium channels and prolongs the QT interval. Cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. These cases appear to b ...
Seeing Through the MIST: Abundance Versus Percentage
... In Type C toxicity, the effect of the drug is due to a chemical reaction between drug or metabolite and tissue macromolecules resulting in a rapidly ensuing response. It is rare that drugs themselves elicit this type of toxicity (an exception is direct alkylating agents used in cancer chemotherapy) ...
... In Type C toxicity, the effect of the drug is due to a chemical reaction between drug or metabolite and tissue macromolecules resulting in a rapidly ensuing response. It is rare that drugs themselves elicit this type of toxicity (an exception is direct alkylating agents used in cancer chemotherapy) ...
PRODUCT INFORMATION NUELIN SR TABLETS
... Nuelin SR is a sustained release formulation appropriate for long term use. Steady-state conditions are usually achieved after 4 days' therapy. It is now generally believed that plasma concentrations of 10-20 µg/mL constitute a therapeutic range, although some patients may benefit from levels below ...
... Nuelin SR is a sustained release formulation appropriate for long term use. Steady-state conditions are usually achieved after 4 days' therapy. It is now generally believed that plasma concentrations of 10-20 µg/mL constitute a therapeutic range, although some patients may benefit from levels below ...
KETOCONAZOLE TABLETS USP 200 mg Rx Only WARNING
... In rare cases anaphylaxis has been reported after the first dose. Several cases of hypersensitivity reactions including urticaria have also been reported. Coadministration of Ketoconazole Tablets and terfenadine has led to elevated plasma concentrations of terfenadine which may prolong QT intervals, ...
... In rare cases anaphylaxis has been reported after the first dose. Several cases of hypersensitivity reactions including urticaria have also been reported. Coadministration of Ketoconazole Tablets and terfenadine has led to elevated plasma concentrations of terfenadine which may prolong QT intervals, ...
RM-0106.02
... Geriatric Use Clinical studies of vancomycin HCl for oral use did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and yo ...
... Geriatric Use Clinical studies of vancomycin HCl for oral use did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and yo ...
Product Monograph
... has been seen in animal studies. The hematopoietic effects occurred at oral doses of 40 and 80 mg/kg/day in dogs and rats, respectively (at exposures approximately 0.6 times in the dog and equal in the rat to the expected human exposure based on AUC). Hematopoietic effects were reversible, although ...
... has been seen in animal studies. The hematopoietic effects occurred at oral doses of 40 and 80 mg/kg/day in dogs and rats, respectively (at exposures approximately 0.6 times in the dog and equal in the rat to the expected human exposure based on AUC). Hematopoietic effects were reversible, although ...
Noxafil - Merck.com
... Noxafil injection should be avoided in patients with moderate or severe renal impairment (creatinine clearance <50 mL/min), unless an assessment of the benefit/risk to the patient justifies the use of Noxafil injection. (5.4, 8.6) Midazolam: Noxafil can prolong hypnotic/sedative effects. Monitor ...
... Noxafil injection should be avoided in patients with moderate or severe renal impairment (creatinine clearance <50 mL/min), unless an assessment of the benefit/risk to the patient justifies the use of Noxafil injection. (5.4, 8.6) Midazolam: Noxafil can prolong hypnotic/sedative effects. Monitor ...
HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------CONTRAINDICATIONS-------------------------------
... and prolonged nucleoside exposure may be risk factors. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. The combination of didanosine and stavudine should be used with caution during pregnancy and is ...
... and prolonged nucleoside exposure may be risk factors. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. The combination of didanosine and stavudine should be used with caution during pregnancy and is ...
8 Ultra-low-dose opioid antagonists enhance opioid analgesia while
... irritability, muscular jerks, abdominal pain, diarrhea, burning sensations, "gooseflesh," and itching (Miser et al., 1986; Heit, 2003). Abrupt cessation of opioid treatment can also cause a hyperalgesia, which has also been called opioidinduced hyperalgesia (Li et al., 2001). While patients receivin ...
... irritability, muscular jerks, abdominal pain, diarrhea, burning sensations, "gooseflesh," and itching (Miser et al., 1986; Heit, 2003). Abrupt cessation of opioid treatment can also cause a hyperalgesia, which has also been called opioidinduced hyperalgesia (Li et al., 2001). While patients receivin ...
clindamycin phosphate vaginal cream
... formulations of clindamycin. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of clindamycin, even when administered by the vaginal route, because approximately 5% of the clindamycin dose is systemically absorbed from the va ...
... formulations of clindamycin. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of clindamycin, even when administered by the vaginal route, because approximately 5% of the clindamycin dose is systemically absorbed from the va ...
Macrolid es, Ketolid es, a nd Glyc ylc yclines : Azithromyc in,
... first-pass metabolism, which results in an absolute oral bioavailability of 57%.23 The bioavailability, rate, and extent of absorption of telithromycin are unaffected by food.24 The single-dose pharmacokinetics of erythromycin, clarithromycin, azithromycin, and telithromycin are summarized in Table ...
... first-pass metabolism, which results in an absolute oral bioavailability of 57%.23 The bioavailability, rate, and extent of absorption of telithromycin are unaffected by food.24 The single-dose pharmacokinetics of erythromycin, clarithromycin, azithromycin, and telithromycin are summarized in Table ...
Prescribing Information
... ASMANEX HFA because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of ...
... ASMANEX HFA because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of ...
results - Pakistan Journal of Pharmaceutical Sciences
... Fredholm et al., 2013 reported accumulation of 1mg/kg P.O. (Per Oss) meloxicam in plasma up to 5 days and suggested a washout period of 10 days with meloxicam. In the present case on day 10 as the drug is almost completely eliminated from the body the values returned to normal. Musa and Ibrahim (201 ...
... Fredholm et al., 2013 reported accumulation of 1mg/kg P.O. (Per Oss) meloxicam in plasma up to 5 days and suggested a washout period of 10 days with meloxicam. In the present case on day 10 as the drug is almost completely eliminated from the body the values returned to normal. Musa and Ibrahim (201 ...
Phenytoin vs fosphenytoin
... and cording in a blind manner. Follow-up continued for 120 hours after the infusion. All 12 patients reported pain at the infusion site during the phenytoin infusion, while only 2 reported pain in this area during the fosphenytoin administration. Eight subjects experienced phlebitis with phenytoin, ...
... and cording in a blind manner. Follow-up continued for 120 hours after the infusion. All 12 patients reported pain at the infusion site during the phenytoin infusion, while only 2 reported pain in this area during the fosphenytoin administration. Eight subjects experienced phlebitis with phenytoin, ...
Introduction
... shown in table 1. Plasma concentration data were fit to a two compartment (biexponential) model, after applications of residual methods. Calculated pharmacokinetic parameters are reported in table 2. In table 3, the median, minimum, and maximum values of plasma concentration of ranitidine of the new ...
... shown in table 1. Plasma concentration data were fit to a two compartment (biexponential) model, after applications of residual methods. Calculated pharmacokinetic parameters are reported in table 2. In table 3, the median, minimum, and maximum values of plasma concentration of ranitidine of the new ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.